EQUITY

3 Months Ended

Mar. 31, 2026

Investments, Debt and Equity Securities [Abstract]

EQUITY

NOTE 5 - MARKETABLE SECURITIES

As of December 31, 2025, all of the Company’s marketable securities had contractual maturities of less than one year.

The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the three-month periods ended March 31, 2026, and 2025:

	Three months ended March 31,
	2026			2025
	($ in thousands)
Balance at beginning of the period	$	45,272		$	15,721
Additions		-			6,909
Maturity		(15,000	)		(9,000	)
Interest Received		(378	)		(69	)
Changes in fair value during the period		314			142
Balance at end of the period		30,208			13,703

NOTE 6 - EQUITY:

a.	Authorized Capital Stock
	As of March 31, 2026, the Company had 155,000,000 authorized shares of capital stock, par value $0.0001 per share, of which 150,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock.
b.	Preferred Stock
	As of March 31, 2026, there were 1,718 shares of Series C preferred stock outstanding, convertible into an aggregate of 7,952 shares of the Company’s common stock, with a total stated value of $10,997.

c.	Pre-Funded Warrants
	As of March 31, 2026, there are 43,092,107 outstanding pre-funded warrants.
d.	Warrants
	As of March 31, 2026, the Company has outstanding warrants to purchase an aggregate of 25,828,164 shares of common stock as follows:

	Number of underlying Common stock		Exercise price		Expiration date
Series J Warrants		12,914,086		1.3827		*
Series K Warrants		12,914,078		1.3827		*
Total Warrants		25,828,164

* The Series J Warrants and Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 cm and (B) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of CGuard Prime in the U.S. begins. Following the commencement of the first commercial sales of CGuard Prime in the United States, which occurred during the third fiscal quarter of 2025 in July 2025, the Series K Warrants are scheduled to expire twenty (20) trading days after the end of the fourth fiscal quarter thereafter, which is October 28, 2026.

During the three months ended March 31, 2026, a total of 1,092,344 Series G warrants expired unexercised.

e.	Share-Based Compensation
	During the three months ended March 31, 2026, the Company granted 3,583,055 restricted shares of the Company’s common stock to employees and directors. The shares granted to employees are subject to a three-year vesting period, with one-third of such awards vesting each year, subject to continued service. The shares granted to directors are subject to a one-year vesting period, subject to continued service.
	The fair value of the above restricted shares was approximately $5.7 million.
	During the three months ended March 31, 2026, the Company granted 1,114,792 restricted stock units convertible into shares of the Company’s common stock to the Company’s chief executive officer. The restricted stock units are subject to a three-year vesting period, with one-third of such awards vesting each year, subject to continued service.
	The fair value of the above restricted share units was approximately $1.8 million.